Loading...
01/10 16:25
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
Total consolidated revenue EUR 64.8 million, a decrease of 5.8% year-over-year. The decline was due to intensified geopolitical and macroeconomic turbulence, as well as the unfavorable effect of a weaker U.S. dollar.
Gross profit margin 58.3%, an increase from 57% in Q2 2024. This improvement was attributed to changes in the revenue mix and optimization of direct production costs despite inflationary pressures.
Adjusted EBIT EUR 3.1 million, down from EUR 3.9 million in Q2 2024. The decrease was due to lower revenue, but targeted cost control measures helped mitigate the impact.
Net result Profit of EUR 0.2 million, despite being negatively impacted by large unfavorable effects from exchange rate fluctuations.
Free cash flow Positive for the first half of 2025, leading to a net cash position of EUR 63 million at the end of Q2, an increase of EUR 2 million compared to the beginning of the year.
Materialise Medical revenue Increased by almost 17% year-over-year, driven by 14% growth in Medical Software and 18% growth in Medical Devices sales. This was attributed to continued growth in direct and partner sales.
Materialise Software revenue Decreased by 12% year-over-year to EUR 9.9 million. The decline was due to the transition to a recurring revenue model, macroeconomic uncertainty, and unfavorable foreign exchange rates.
Materialise Manufacturing revenue Decreased by almost 25% year-over-year to EUR 22.1 million. The decline was driven by geopolitical uncertainty and macroeconomic headwinds, particularly in the Automotive segment.
Adjusted EBITDA for Materialise Medical EUR 10.7 million, with an increased adjusted EBITDA margin of 32.7%, reflecting strong revenue growth and planned R&D investments.
Adjusted EBITDA for Materialise Software EUR 1.4 million, representing a stable adjusted EBITDA margin of 14%, despite lower revenue due to effective cost management.
Adjusted EBITDA for Materialise Manufacturing Negative EUR 0.8 million, slightly below the result of the first quarter of 2025, but significantly improved from the last quarter of 2024. The improvement was due to cost control and a focus on strategic areas.
Gross profit EUR 37.8 million, representing a gross profit margin of 58.3%, up from 57% in Q2 2024. The increase was due to mix effects and production efficiencies.
Operating expenses Decreased by close to 1% year-over-year, with R&D expenses remaining flat and reductions in sales, marketing, and G&A expenses due to cost optimizations.
Net financial result Loss of EUR 3.1 million, including a significant negative impact from foreign exchange fluctuations of minus EUR 3.3 million.
Mimics Thoracic Planner: A 3D surgical planning solution for thoracic surgery to treat lung cancer patients. It enables minimally invasive care and lung-sparing procedures. A pilot collaboration with Johnson & Johnson's Surgical business in EMEA was announced to advance adoption.
Personalized Knee Guides: Received 510(k) U.S. market clearance for a personalized alignment feature in knee surgery. This innovation tailors knee implant positioning to each patient's unique anatomy and will be launched in the U.S. market in Q3 2025.
Magics SDK Collaboration with Synera: Integration with Synera's AI platform to automate additive manufacturing workflows, reducing manual effort and costs while improving efficiency.
Respiratory Market Expansion: Developing the respiratory market with solutions like the Mimics Thoracic Planner, targeting thoracic surgery and lung cancer treatment.
Defense Sector Engagement: Announced a strategic decision to engage with the defense sector, enhancing regional defense capabilities and strengthening the aerospace segment.
Cost Control Measures: Implemented restructuring in the Manufacturing division, reassessed core activities, and reclassified some assets as held for sale to manage costs amid revenue pressure.
Recurring Revenue Model in Software: Continued transition to a cloud subscription-based model, with 84% of Software revenue now recurring.
Focus on Strategic Market Segments: Targeted specific customer and market segments in Software and Manufacturing to drive growth despite macroeconomic challenges.
Partnerships for Additive Manufacturing: Collaborated with Synera to enhance end-to-end workflows in additive manufacturing, enabling scalability and efficiency.
Geopolitical volatility and macroeconomic uncertainty: The company faces headwinds due to geopolitical volatility and macroeconomic uncertainty, which are impacting customer investment decisions and delaying projects. This is particularly affecting the Software and Manufacturing segments.
Decline in Software and Manufacturing revenue: Revenues from the Software and Manufacturing segments declined by 12% and 25%, respectively, due to intensified geopolitical and macroeconomic turbulence. This has led to a decrease in consolidated revenue.
Foreign exchange fluctuations: The company experienced large unfavorable effects from exchange rate fluctuations, which negatively impacted net financial results.
Pressure on Manufacturing segment: The Manufacturing segment is under severe pressure, particularly in the Automotive sector, leading to a 25% revenue decline. The company has had to restructure and reclassify some assets as held for sale.
Transition to cloud subscription model: The transition to a cloud subscription-based business model in the Software segment is putting pressure on sales volumes, especially in the U.S. market.
Restructuring and cost control: The company has implemented restructuring and cost control measures, including stopping metal prototyping operations, to manage costs amid revenue pressures.
Unfavorable market conditions: The company anticipates that geopolitical volatility, macroeconomic uncertainty, and unfavorable foreign exchange fluctuations will continue to impact the business climate for the remainder of 2025.
Revenue Guidance: The company has slightly reduced its revenue guidance for the full year 2025 from the earlier communicated range of EUR 270 million to EUR 285 million to a range of EUR 265 million to EUR 280 million.
Adjusted EBIT Guidance: Despite the slightly lower revenue outlook, the company is reconfirming its adjusted EBIT guidance range of EUR 6 million to EUR 10 million for fiscal year 2025.
Market Conditions: The company anticipates intensified geopolitical volatility and macroeconomic uncertainty to further impact the business climate for the remainder of 2025. Unfavorable foreign exchange fluctuations might also add pressure on revenue and reported net results.
Cost Management: The company plans to continue implementing structural cost efficiencies to safeguard operational profitability despite the challenging market environment.
Medical Segment Growth: The Medical segment is expected to continue its strong performance, driven by high double-digit growth and strategic R&D investments.
Manufacturing Segment Focus: The company has decided to stop its metal prototyping operations and focus exclusively on metal series production to align with strategic priorities and reduce costs.
Software Segment Transition: The company is continuing its transition to a cloud subscription-based business model, with 84% of Software revenue now of a recurring nature.
Future Investments: The company plans to continue R&D investments, particularly in the Medical segment, to drive future growth and achieve strategically important milestones.
The selected topic was not discussed during the call.
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
The earnings call reveals a mixed performance with a 4% revenue increase but a significant drop in EBIT and net profit, indicating financial struggles. The guidance remains flat, and management's vague responses in the Q&A add uncertainty. Competitive pressures, regulatory issues, and economic factors pose risks. Despite positive cash flow and R&D investments, the negative trends in manufacturing and software revenues, coupled with unclear future projections, suggest a negative sentiment. The lack of market cap data prevents a more precise prediction, but the overall sentiment leans negative.
The earnings call highlights strong financial performance with a 14% revenue increase, improved margins, and successful acquisitions. Despite some management ambiguity during the Q&A, the optimistic guidance, new partnerships, and ongoing investments suggest positive market sentiment. The medical segment's growth and strategic partnerships are key catalysts for a potential stock price increase, likely in the 2% to 8% range.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
